Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,804 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus - Type 1 Clear all
Completed Phase 2 Interventional Results available

Combination Immunotherapy in Colorectal Cancer

NCT05571293
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Recruiting No phase listed Observational

Home-based Oral Glucose Tolerance Test for Type 1 Diabetes Screening

NCT07155252
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
GTT@Home
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
8 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
No Longer Available No phase listed Expanded access

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

NCT01798914
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
Technosphere Insulin Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
14
States / cities
Montgomery, Alabama • Miami, Florida • Orland Park, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Fuzzy Logic Automated Insulin Regulation

NCT03040414
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
MedtronicMinimed 670G 3.0 hybrid closed loop system, Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
14 Years to 30 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
New Haven, Connecticut • Gainesville, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 16, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

NCT00747006
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Identifying Driving Risk Factors in Type 1 Diabetes and Their Reduction Via Internet Program (DiabetesDriving.Com)

NCT01563887
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
DD.com, DD.com + MI
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
568 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 16, 2026, 10:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Detection of Human Beta Cell Death in Type 1 Diabetes Mellitus (T1DM) by Methylation Specific Polymerase Chain Reaction (PCR)

NCT01176253
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Blood draw
Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
2
States / cities
Duarte, California • Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 16, 2026, 10:45 PM EDT
Completed No phase listed Observational

Vascular Inflammation in Adolescents With Type 1 Diabetes

NCT00933101
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 16, 2026, 10:45 PM EDT
Active, not recruiting No phase listed Observational

Evaluating the InPen in Pediatric Type 1 Diabetes

NCT05515939
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
InPen Insulin Pen
Device
Lead sponsor
Wayne State University
Other
Eligibility
13 Years to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Terminated Phase 2 Interventional Results available

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

NCT03895437
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
TOL-3021, TOL-3021 Placebo
Biological · Other
Lead sponsor
Tolerion, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
23
States / cities
San Diego, California • San Francisco, California • San Mateo, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes

NCT01855490
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exenatide
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 56 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 7, 2016 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 4 Interventional

Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus

NCT04030091
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
3 hours humulin R 100 IU/mL PIT, 2 hours humulin R 100 IU/mL PIT
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 16, 2026, 10:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

NCT07675590
View directory record Official record
Conditions
Health Adult Subjects, Obesity & Overweight
Interventions
TIX100, Placebo
Drug
Lead sponsor
TIXiMED, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Pivotal Omnipod Horizon™ Automated Glucose Control System

NCT04196140
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Horizon™ Automated Glucose Control System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
6 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
16
States / cities
Palo Alto, California • Santa Barbara, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 16, 2026, 10:45 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD6234, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
33
States / cities
Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Active, not recruiting Not applicable Interventional

Device Use Reimagined Through Education And Mentorship

NCT06546930
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
DREAM intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Davis, California • Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

NCT00046501
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
9 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Outpatient Pump Shutoff Pilot Feasibility and Efficacy Study

NCT01591681
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pump suspension
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
15 Years to 45 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

Metformin Therapy for Overweight Adolescents With Type 1 Diabetes

NCT01881828
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Metformin (glucophage), oral placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years to 19 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Feasibility Trial Testing the Bionic Pancreas With ZP4207

NCT02971228
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
Drug · Device
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Strategies to Enhance New CGM Use in Early Childhood (SENCE)

NCT02912728
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
CGM + Family Behavioral Intervention, Standard CGM
Behavioral · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
2 Years to 7 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)

NCT00073255
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
hokt3g1 (ALA-ALA)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 16, 2026, 10:45 PM EDT
Completed Not applicable Interventional

Effects of Web-Based Health Information on Risk Behavior for Youth With Type 1 Diabetes in College

NCT02883829
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Peer-Based Web-Based Health Information, Provider-Based Web-Based Health Information
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
17 Years to 25 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 16, 2026, 10:45 PM EDT
Not listed Phase 3 Interventional

Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetes

NCT01023165
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Integrity
Interventions
Humulin, Humalog, Novolog
Procedure
Lead sponsor
Global Infusion and Aspiration Systems, LLC
Other
Eligibility
18 Years to 95 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Batesville, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 16, 2026, 10:45 PM EDT